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Sixty-three patients with Salmonella typhi infections were randomly assigned to receive
either ceftriaxone iv in single daily doses of 75 mg/kg for children and 3-4 g for adults
for seven days or to receive60 mg of chloramphenicol/kg a day orally or iv in four divided
doses until defervescence and then 40 mg/kg a day to complete 14 d. In the ceftriaxone
group, one death occurred, and two of seven patients still febrile 11 d after starting treat-
ment were given chloramphenicol. In the chloramphenicol group, one death and one gas-
trointestinal perforation occurred. The probability of remaining febrile was similar for
both groups during the first seven days but was significantly greater for patients receiving
ceftriaxone during the 14-dperiod. Patients in the chloramphenicol group weremore likely
to be bacteremic on day 3. These results suggest that a seven-day course of once-daily
ceftriaxone shows promise as an alternative to 14 d of chloramphenicol for treating ty-
phoid fever.
Chloramphenicol has remained the drug of choice
for typhoid fever for >35 y because no newer anti-
microbial drug has been shown to givebetter or more
consistent clinical improvement at a comparable
cost. In vitro resistance to chloramphenicol has been
a rare and sporadic problem [1]. Nevertheless, there
are important disadvantages - (1)treatment does not
prevent chronic fecal carriage of Salmonella typhi,
relapsesafter the end of therapy, or the complications
of intestinal perforation and bleeding; (2) residual
mortality occurs during therapy; (3) reversible bone
marrow suppression develops and rare aplastic ane-
mia is a risk; and (4) the course of treatment requires
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administering the drug four times a day for two
weeks. Shorter courses of chloramphenicol are not
advised, because relapses occur in 10070-20070 of
treated cases one to two weeks after therapy.
Ceftriaxone is a newer cephalosporin antibiotic
with good in vitro activity, as shown by MICs of
0.05 ug/ml, for most tested strains of Salmonella
[2].Penetration of this antibiotic into tissues and par-
ticularly into cells [3, 4] indicates that it might be
activeagainst the intracellular pathogen S. typhi. The
prolonged serum half-life of 8 h and biliary excre-
tion of ceftriaxone permit less-frequent doses for en-
teric infections [5,6]. The use of ceftriaxone for treat-
ing murine typhoid showed a good therapeutic effect
[7], and an open trial with 14 patients with typhoid
fever in Singapore produced cures in 13patients [8].
Materials and Methods
Selection ofpatients. Adults and children who
reported to the International Centre for Diarrhoeal
Disease Research, Bangladesh between June 1984
and December 1985 were considered for inclusion
in the study. Criteria for initial inclusion were age
(six months to 60 y), fever (for four or more days),
diarrhea (at least three liquid stools in the past 24 h),
abdominal pain or tenderness, and 0 agglutinin titer
Islam et al.
(~80 for S. typhii. Patients were excluded if they had
a history of effective antimicrobial therapy within
one week before hospitalization, known allergy to
penicillin or cephalosporin, or other complications
(including gastrointestinal hemorrhage or perfora-
tion) or jaundice. The patients were randomly as-
signed to receive chloramphenicol or ceftriaxone by
using a table of random numbers. Only those pa-
tients with cultures of blood or stool that were posi-
tive for S. typhi were studied.
Assessment ofpatients and bacteriologic investi-
gations. Histories and physical examinations were
completed before therapy began. Rectal tempera-
tures, pulse rates, and blood pressures were recorded
at 8-h intervals. Frequency and consistency of stools
were recorded every 8 h. Stools were cultured for
Salmonella, Shigella, Vibrio, Campylobacter, and en-
terotoxigenic Escherichia coli (ETEC). Physical ex-
amination and vital signs were followed up until the
end of the 14-d stay at the hospital. On admission,
blood, stool, and urine were cultured by using stan-
dard methods. Isolated strains of S. typhi were sent
to the Enteric Reference Laboratory (Colindale, En-
gland), where Vi-phage typing was performed. The
isolated strains were also tested for antimicrobial sus-
ceptibility by using agar diffusion. Ceftriaxone disks
containing 30 IJ.g ofantibiotic were used; a clear zone
of >16 mm in diameter indicated susceptibility.
Laboratory investigations. Before therapy was
begun, fecal specimens were examined microscopi-
cally for leukocytes, ova, parasites, and occult blood
(guaiac test). Urine was also microscopically exam-
ined. Blood was obtained for complete blood counts
and for determining concentrations of creatinine and
electrolytes. Serum concentrations of ceftriaxone
and chloramphenicol were determined by high-per-
formance liquid chromatography [9, 10] on speci-
mens taken 24 h after a dose of ceftriaxone and 6 h
after a dose of chloramphenicol on days 3 and 7 of
treatment. Cultures of blood were repeated on days
3 and 14. Repeated complete blood counts and stool
cultures were done on days 7 and 14.
Therapy. After all initial diagnostic specimens
had been collected, therapy was started according
to one of two drug regimens. Chloramphenicol was
given orally or iv in four divided doses daily for 14 d.
Adults and children received chloramphenicol (Kemi-
cetenes; Farmitalia Carlo Erba, Italy) in doses of
60 mg/kg of body weight per day until defervescence.
The dose was then reduced to 40 mg/kg per day to
complete the 14-d regimen. Ceftriaxone (F. Hoff-
743
man-La Roche, Basel, Switzerland) was administered
iv over 30 min in a single daily dose for seven days.
Adults received 3 or 4 g and children received
75 mg/kg per day. We monitored adverse drug ef-
fects during therapy, such as urticaria, rashes, nau-
sea, vomiting, and phlebitis. During the first week
in the hospital, patients received no drugs other than
chloramphenicol and ceftriaxone. Dexamethasone
was not given.
Assessment oftreatment. Patients were consid-
ered clinically cured if they survived, became afebrile
without a major complication (perforation or bleed-
ing), did not require retreatment for typhoid fever,
and did not experience relapse after discharge. Pa-
tients were considered bacteriologically cured if their
cultures of blood were negative for S. typhi at the end
of treatment. The first afebrile day was defined as
the first day the patient's rectal temperature dropped
to ~37.8 C and remained there for at least 48 h.
Defervescence of patients was analyzed statistically
using Kaplan-Meier estimates of probability of re-
maining febrile. Comparisons of estimates were done
with a generalized Savage (Mantel-Cox) test (BMDP
Statistical Software, Los Angeles). Diarrhea was con-
sidered to have ended when patients passed their last
liquid stool. Relapse was defined as return of symp-
toms and isolation of S. typhi from the blood within
two months after the start of therapy. Patients were
instructed to report to the hospital if they became
febrile after discharge from the hospital. Patients
were also asked to return after one week from the
date of discharge for follow-up examination.
Results
Characteristics ofpatients and bacterial strains.
A total of 63 patients with blood and/or stool iso-
lates of S. typhi were studied (29 adults and 34 chil-
dren <16 y old). By random assignment, 31 received
chloramphenicol, and 32 received ceftriaxone. The
sex ratios, means of ages, and durations of fever and
diarrhea before admission were similar in the two
treatment groups (table 1). Frequencies of spleno-
megaly, hepatomegaly, coated tongue, rose spots,
and delirium, obtundation (a depressed level of con-
sciousness), or stupor were also comparable in the
two groups. Among the 63 patients, 84070 in the
chloramphenicol group and 88070 in the ceftriaxone
group had cultures of blood that were positive for
S. typhi. Stool cultures were positive for S. typhi in
35070 of patients in the chloramphenicol group and
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Table 1. Presenting features of patients with typhoid
fever, according to treatment group.
* Data are numbers, means ± SD, and percentages. No sig-
nificant differences were noted between the treatment groups
(P> .05).
in 56010 of patients in the ceftriaxone group. In the
chloramphenicol group, four patients were given the
drug iv during part of the hospital course because
of delirium or abdominal distention.
All S. typhi isolates from the 63 patients were sus-
ceptible to ampicillin, chloramphenicol, trimetho-
prim-sulfamethoxazole, gentamicin, kanamycin, na-
lidixic acid, and ceftriaxone. Strains from 45 patients
weretested to determine their Vi-phage type at Colin-
dale, England. The distribution of Vi-phage types was
five of Ml; four each of A and untypable Vi-strain
2; three each of 53, T, Jl, and degraded Vi-strain 4;
two each of degraded Vi-strain, Vi-negative strain,
Dl, El, and J variant; and one each of untypable
Vi-strain 1, Cl, D2, F4, J5, Kl, 28, 32, 46, and 51.
Other enteric pathogens identified in stools from
patients in the ceftriaxone group included three with
trophozoites of Entamoeba histolytica and one each
of Shigella dysenteriae type 1, Shigella boydii, Vibrio
cholerae, and ETEC. In the chloramphenicol group,
one patient each had trophozoites of E. histolytica,
S. boydii, and Jt: cholerae.
Outcomeoftherapy. Twenty-nine patients (94%)
treated with chloramphenicol and 29 (91%) treated
with ceftriaxone wereclinically cured and discharged
without gastrointestinal perforation, need for retreat-
ment, or relapse (table 2). One death occurred in each
Drug treatment*
3
o
29
1
2
o
Ceftriaxone
(n = 32)
Drug treatment
29
1
o
1
Chloramphenicol
(n = 31)Outcome
Cure*
Death
Need for retreatment
Intestinal perforation
Other complications
Pneumonia
Peritonitis
NOTE. Data are no. of patients.
* Patients were considered cured if they survived, became
afebrile without a major complication, did not require retreat-
ment, and did not have a relapse.
Table 2. Outcomes of treatment, by treatment group.
group. In the chloramphenicol group a 20-y-old
woman with a one-month history of fever and an-
orexia died, on the fourth hospital day, ofacute bron-
chitis and pneumonia. In the ceftriaxone group a 25-
y-old woman with a one-week history of fever and
stupor died, on the third hospital day, of pneumonia
and hypotension. One patient in the chlorampheni-
col group developed intestinal perforation on the sev-
enth hospital day, underwent surgical treatment, and
survived. On the 11th hospital day, two patients in
the ceftriaxone group who were still febrile received
chloramphenicol. They both had negative cultures
of blood at the time chloramphenicol was started.
The time required for defervescence ranged from
4 to 13 d in patients treated with chloramphenicol
and from 4 to >14 d in patients treated with ceftri-
axone. The probability of remaining febrile was simi-
lar in the two treatment groups during the first seven
days after the start of therapy, but when considering
the entire 14d, patients treated with ceftriaxone had
a higher probability of remaining febrile (figure 1;
P < .05). In seven patients treated with ceftriaxone
who were febrile >10 d, two had clinical signs of
pneumonia, and one had amebic trophozoites in his
stool. The other patients with prolonged fevershowed
no signs of complications, no eosinophilia, no drug
rash, and the causes of fever could not be ascer-
tained. Cessation of diarrhea after start of treatment
was more rapid for patients treated with ceftriaxone
than for patients treated with chloramphenicol
(mean, 2.7 d and 4.0 d, respectively; P < .05).
On the eighth hospital day, one patient in the
ceftriaxone group received metronidazole for ame-
biasis. Six weeks after the end of treatment, one pa-
13
66
38
28
9
69
88
56
9.7 ± 5.4
6.7 ± 5.9
32 (24/8)
14.7 ± 8.2
3
52
19
26
10
65
84
35
5.6 ± 3.8
10.3 ± 4.6
31 (21/10)
14.6 ± 7.4
Chloramphenicol Ceftriaxone
No. of patients
(males/ females)
Age (y)
Duration of fever before
admission (d)
Duration of diarrhea before
admission (d)
Percentage of patients with
Splenomegaly
Hepatomegaly
Rose spots
Delirium
Obtundation or stupor
Coated tongue
Positive culture of blood
Positive stool cultures
Characteristic
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Figure 1. The probability of remaining febrile on each
day after the start of treatment. Thirty-one patients were
treated with chloramphenicol (.) and 32 were treated with
ceftriaxone (0). Two patients who died and one who de-
veloped an intestinal perforation wereremoved from anal-
ysis one day after the event.
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Figure 2. Trough serum concentrations of antibiotic.
Ceftriaxone concentrations weremeasured 24 h after daily
iv injections; chloramphenicol concentrations were mea-
sured 6 h after oral or iv treatments. Dots represent con-
centrations in individual patients. Barsshow the mean con-
centrations on designated days.
tient in the ceftriaxone group experienced a reinfec-
tion with a Vi-negative strain of S. typhi; this strain
was different from the Vi-phage type D2 that had
caused the original illness.
Bacteriologic response. All of the patients treated
with ceftriaxone had negative cultures of blood on
the third day of treatment, whereas 52% of patients
treated with chloramphenicol had positive cultures
(P <.05 by Fisher's exact test). All cultures of blood
were sterile on the 14th day after the start of therapy
in both groups. Repeat stool cultures on hospital days
7 and 14 were all negative for S. typhi. Sixteen pa-
tients in the chloramphenicol group and 21 patients
in the ceftriaxone group returned approximately one
week after the time of discharge for examination and
rectal swab cultures. All cultures were negative for
S. typhi.
Drug concentrations in serum. Trough serum
concentrations of ceftriaxone after daily injections
on days 3 and 7 of treatment ranged from 0.9 to
56 J.1g/mL. The mean concentrations on day 3 of 11.9
J.1g/mL and on day 7 of 11.5 ug/ml, indicated that
antibiotic did not accumulate in the blood during the
treatment period (figure 2). The trough serum con-
centrations of chloramphenicol after six-hourly treat-
ments on days 3 and 7 ranged from 5.5 to 57 J.1g/mL.
Thirteen patients had trough values >20 J.1g/mL,
which is the trough concentration of chlorampheni-
col associated with suppression of erythropoiesis [11].
Assays of chloramphenicol in selected vials and cap-
sules of the lots used in the study showed that the
vials contained 1210/0 of the predicted amount; the
capsules stated to contain 250 mg actually contained
an average of 259.2 mg.
Hematologic repsonses. The mean hematocrit
values decreased progressively during the two weeks
after initiation of treatment in both treatment groups
(figure 3). The mean white blood cell counts increased
at day 7 and day 14after the start ofceftriaxone treat-
ment to levels that were significantly higher than
those in the chloramphenicol group (P < .05). Like-
wise, the mean platelet count on hospital day 14was
higher in patients treated with ceftriaxone than in
patients treated with chloramphenicol (P < .01).
Discussion
Our experience with treating typhoid fever with a
seven-day course of ceftriaxone showed cure rates
comparable to those for standard treatment with
chloramphenicol. Important differences between the
two treatments, however, were an earlier resolution
of bacteremia and a higher proportion of patients
remaining febrile for ~10 d after the start of treat-
ment in the group that received ceftriaxone. Blood
levels of ceftriaxone measured 24 h after the previ-
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Figure 3. Hematologic responses during treatment. Val-
ues are given as means (bars, SE) before treatment and
on hospital days 7 and 14.Asterisk, P< .05; star, P< .01.
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ous doses were in a good therapeutic range, an ob-
servation confirming that the long half-life of this
drug permits one daily dose [5].
In patients treated with ceftriaxone, the time re-
quired for defervescence ranged from 4 to >14 d, with
23% of patients remaining febrile >10 d. These
prolonged fevers were not explained by bacteriologic
failure, inadequate blood levels of drug, or drug fe-
ver. Most of these patients were clinically improved
in other respects and went on to be cured. This pat-
tern of defervescence resembles Sanders' experience
[12] with ampicillin in Indonesia. Sanders found that
patients with severe typhoid fever failed to respond
to ampicillin and had longer febrile courses than did
patients treated with chloramphenicol; similarly,
Robertson et al. [13] reported that 23070 of patients
in Egypt who were treated with ampicillin still had
fever after 10 d of treatment. In Mexico, Gilman et
al. [14] similarly showed that patients treated with
amoxicillin defervesced more slowly than patients
treated with trimethoprim-sulfamethoxazole. A pos-
sible explanation for prolonged fevers in some pa-
tients treated with ceftriaxone was that they had coin-
fections with other enteric bacteria or respiratory
pathogens that were more effectively treated by
chloramphenicol. Alternatively, ceftriaxone treat-
ment may have reduced the burden of bacteria in the
body below the leveldetectable by cultures of blood,
but residual intracellular S. typhi, which might have
been detectable by bone marrow culture [15], could
have continued to cause fever while gradually being
eliminated by the immune response.
The experiences of other investigators with newer
cephalosporins have also indicated that these drugs
may be satisfactory alternatives to chloramphenicol
for treating typhoid fever. Ceftriaxone was used suc-
cessfully in 13 of 14 patients with typhoid fever in
an open study in Singapore [8], although three pa-
tients did not defervesceduring treatment. In another
open study of 19 patients with typhoid fever in Tai-
wan, who received ceftriaxone for only two to three
days, 16 patients were judged successfully treated,
whereas two patients had prolonged fevers, and one
had a relapse [16]. Cefoperazone has been reported
as successful treatment of typhoid fever in Haiti [17]
and France [18]. Similarly, cefotaxime was given to
45 patients with typhoid fever in Korea; all defer-
vesced in three to 14 days, and only one had a re-
lapse [19]. Cefamandole givento nine patients in leb-
anon cured six patients, with defervescenceoccurring
after three to nine days of treatment [20].
Chloramphenicol is likely to remain the drug of
choice for disease caused by chloramphenicol-sus-
ceptible strains, because chloramphenicol is cheaper,
readily available for both oral and parenteral use,
and regularly renders patients afebrile within 10 d
after the start of treatment [21, 22]. The role of ceftri-
axone and other newer cephalosporins in typhoid
fever will be in disease due to multiply resistant
strains of S. typhi [23]. From studies of ampicillin-
resistant Salmonella, it can be predicted that certain
cephalosporins, including ceftriaxone, cefotaxime,
and cefoxitin, will havegood therapeutic activity, be-
cause they are more stable in the presence of 13-
lactamase than are other cephalosporins [24].
The potential advantages of ceftriaxone shown in
this study were a shorter course of treatment and the
avoidance of bone marrow suppression by chloram-
phenicol, as shown by faster recovery of leukocyte
and platelet counts. High serum concentrations of
chloramphenicol, at which suppression of the bone
marrow occurs, developed in several of our patients
and could be the result of delayed hepatic metabo-
lism of chloramphenicol in the setting of severe ty-
phoid fever in a developing country. A portion of
the high serum concentrations of chloramphenicol
can be explained by the overfilling of capsules and
vials by the manufacturer, an occurrence that was
detected in our direct assay. Further studies are re-
quired to determine whether the advantages of ceftri-
Chloramphenicol
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b
30 l---'---_-'---_--=_
32
36
Ceftriaxone
Hematocrit 34
Percent
10lc::White Blood Cell 8 ~**
Count per
mm3 x 1,000
6
Treatment of Typhoid Fever
axone justify using this drug rather than chloram-
phenicol for treating patients with typhoid fever.
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